QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
QQQ   291.14 (-4.91%)
AAPL   140.82 (-5.64%)
MSFT   254.08 (-4.77%)
FB   192.24 (-5.12%)
GOOGL   2,237.99 (-3.93%)
AMZN   2,142.25 (-7.16%)
TSLA   709.81 (-6.80%)
NVDA   169.38 (-6.82%)
BABA   87.31 (-5.09%)
NIO   15.83 (-4.81%)
AMD   96.28 (-6.04%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.23 (-1.65%)
GE   75.20 (-1.57%)
F   12.78 (-5.54%)
DIS   104.30 (-3.99%)
AMC   12.76 (-1.09%)
PFE   50.40 (-1.83%)
PYPL   77.18 (-3.22%)
NFLX   177.19 (-7.02%)
NASDAQ:SESN

Sesen Bio (SESN) Stock Forecast, Price & News

$0.51
+0.06 (+13.25%)
(As of 05/18/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.46
$0.54
50-Day Range
$0.38
$0.73
52-Week Range
$0.37
$6.04
Volume
4.80 million shs
Average Volume
3.15 million shs
Market Capitalization
$102.33 million
P/E Ratio
2.05
Dividend Yield
N/A
Beta
0.93
30 days | 90 days | 365 days | Advanced Chart
Receive SESN News and Ratings via Email

Sign-up to receive the latest news and ratings for Sesen Bio and its competitors with MarketBeat's FREE daily newsletter.

Sesen Bio logo

About Sesen Bio

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SESN
Employees
35
Year Founded
N/A

Sales & Book Value

Annual Sales
$26.54 million
Cash Flow
$0.09 per share
Book Value
$0.86 per share

Profitability

Net Income
$-340 thousand
Pretax Margin
206.03%

Debt

Price-To-Earnings

Miscellaneous

Free Float
195,076,000
Market Cap
$102.33 million
Optionable
Optionable

Company Calendar

Last Earnings
2/28/2022
Today
5/18/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.98 out of 5 stars

Medical Sector

621st out of 1,426 stocks

Pharmaceutical Preparations Industry

286th out of 680 stocks

Analyst Opinion: 3.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -













Sesen Bio (NASDAQ:SESN) Frequently Asked Questions

Is Sesen Bio a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sesen Bio in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Sesen Bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SESN, but not buy additional shares or sell existing shares.
View analyst ratings for Sesen Bio
or view top-rated stocks.

When is Sesen Bio's next earnings date?

Sesen Bio is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Sesen Bio
.

How were Sesen Bio's earnings last quarter?

Sesen Bio, Inc. (NASDAQ:SESN) posted its quarterly earnings results on Monday, February, 28th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.10. The business had revenue of $20 million for the quarter.
View Sesen Bio's earnings history
.

What price target have analysts set for SESN?

1 brokers have issued 12-month price objectives for Sesen Bio's shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Sesen Bio's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 1,459.5% from the stock's current price.
View analysts' price targets for Sesen Bio
or view top-rated stocks among Wall Street analysts.

Who are Sesen Bio's key executives?
Sesen Bio's management team includes the following people:
  • Dr. Thomas R. Cannell, Pres, CEO & Director (Age 60, Pay $885.06k)
  • Ms. Monica Forbes, CFO & Treasurer (Age 46, Pay $536k)
  • Dr. Glen C. MacDonald, Chief Technology Officer (Age 71, Pay $519.7k)
  • Dr. Gregory L. Verdine Ph.D., Co-Founder (Age 63)
  • Ms. Elly Ryu, Corp. Controller & Principal Accounting Officer (Age 41)
  • Ms. Erin Clark, VP of Corp. Strategy & Investor Relations
  • Mr. Mark R. Sullivan, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. John Knighton, VP & Chief Compliance Officer (Age 44)
  • Mr. Steve Barbera, VP of Market Access
  • Dr. David Brooks, Sr. VP of Clinical Devel.
What other stocks do shareholders of Sesen Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include Amarin (AMRN), XOMA (XOMA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Verastem (VSTM), Sorrento Therapeutics (SRNE), Novavax (NVAX), Biocept (BIOC), Micron Technology (MU) and OPKO Health (OPK).

What is Sesen Bio's stock symbol?

Sesen Bio trades on the NASDAQ under the ticker symbol "SESN."

Who are Sesen Bio's major shareholders?

Sesen Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.71%), Vanguard Group Inc. (6.36%), State Street Corp (2.18%), Northern Trust Corp (0.87%), Group One Trading L.P. (0.00%) and Bank of New York Mellon Corp (0.32%).

Which major investors are selling Sesen Bio stock?

SESN stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., Simplex Trading LLC, Goldman Sachs Group Inc., BlackRock Inc., Northern Trust Corp, UBS Group AG, and Cutler Group LP.

Which major investors are buying Sesen Bio stock?

SESN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., Stratos Wealth Partners LTD., State Street Corp, Allspring Global Investments Holdings LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., and Venture Visionary Partners LLC.

How do I buy shares of Sesen Bio?

Shares of SESN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sesen Bio's stock price today?

One share of SESN stock can currently be purchased for approximately $0.51.

How much money does Sesen Bio make?

Sesen Bio has a market capitalization of $102.33 million and generates $26.54 million in revenue each year. The company earns $-340 thousand in net income (profit) each year or $0.25 on an earnings per share basis.

How many employees does Sesen Bio have?

Sesen Bio employs 35 workers across the globe.

What is Sesen Bio's official website?

The official website for Sesen Bio is www.sesenbio.com.

How can I contact Sesen Bio?

Sesen Bio's mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The company can be reached via phone at (617) 444-8550, via email at [email protected], or via fax at 617-858-0911.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.